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Botulinum neurotoxins (BoNTs) are known for their ability to induce chemical denervation, modulation
of neurotransmission, and successful long-term treatment of muscle hypercontractility. Recent basic
science studies as well as clinical studies suggest that BoNT affects the modulation of sensory processing,
inﬂammation, and glandular function. Causes of lower urinary tract symptoms (LUTS) include abnor-
malities of the bladder, prostate, urethra, and neurological function that controls the lower urinary tract.
Urologists have become interested in the potential application of BoNTs in patients with LUTS including
detrusor and sphincter overactivity, bladder hypersensitivity, interstitial cystitis/painful bladder symp-
toms, and benign prostatic hyperplasia. In this study we review the biological action of BoNTs in the
bladder and prostate.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Botulinum neurotoxin (BoNT) is one of the most potent toxins
known to date. BoNT is produced by a Gram-positive, rod-shaped
anaerobic bacteriumdClostridium botulinum. It was ﬁrst used
effectively for different conditions involving muscular hyper-
contraction [1,2] by inhibiting acetylcholine (ACh) release at the
presynaptic cholinergic neuromuscular junction. Seven immuno-
logically distinct neurotoxins are available, which are designated as
types A, B, C, D, E, F, and G [1e3]. All these serotypes block trans-
mission at neuromuscular junctions to various degrees. Effects of
type A botulinum neurotoxin (BoNT-A), which is the most used
neurotoxin, have been studied most extensively.
Although BoNT has seven serotypes, only BoNT-A and BoNT-B
are in clinical use. Available brands of BoNT-A include onabotuli-
numtoxinA (Botox; Allergan, Inc., Irvine, CA, USA) and abobotuli-
numtoxinA (Dysport; Ipsen Ltd., Berkshire, UK), and the brand of
BoNT-B includes rimabotulinumtoxinB (Myobloc; Elan Pharma-
ceuticals, Inc., Princeton, NJ, USA). The potency of each toxin is
expressed in units of activity. However, these toxins have different, investigator and researcher
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ddhist Compassion Relief Tzu Chidoses, efﬁcacy, and safety proﬁles and should not be considered
generic equivalents comparable by single dose ratios [3].
BoNT has been applied for the treatment of lower urinary tract
symptoms (LUTS) since the late 1980s. Dykstra et al [4] demon-
strated that an injection of BoNT into the external urethral
sphincter induces chemical sphincterotomy and lowers detrusor-
sphincter dyssynergia in patients with spinal injuries. A resur-
gence of interest in BoNT was led by Schurch et al [5], who reported
successful treatment of spinal-cord-injured patients with neuro-
genic detrusor overactivity (NDO). Maria et al [6] reported the
therapeutic effects of BoNT in patients with benign prostatic hy-
perplasia (BPH). Interestingly, all three pioneers were not urolo-
gists. Chancellor and his group played a major role for urologists to
step into this fascinating ﬁeld [1]. As the uses of BoNT continue to
expand in the ﬁeld of urology, it is important to understand the
mechanism and clinical effects by which the toxin works on
different tissue types and disease entities.2. Working mechanisms of BoNT
BoNT-A was originally synthesized as an inactive chain of 1285
amino acids and is activated when the single chain is cleaved by an
endogenous clostridial protease [1,7]. A dichain polypeptide con-
taining a 50 kDa light chain and a 100 kDa heavy chain linked
covalently by a single disulﬁde bond [7] is created. BoNT-A inhibits
signal transmission at the neuromuscular and neuroglandular
junctions in the following four discrete stages: (1) binding, theFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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ceptor; (2) internalization, the toxin gets into the nerve terminal;
(3) translocation, the light chain of the toxin translocates into the
cytosol; and (4) inhibition of neurotransmitter release, the toxin
attacks active neurons in a receptor-mediated endocytotic process.
BoNT-A is taken up in a neuron activity-dependent manner by
utilizing synaptic vesicle protein SV2 as its protein receptor and
attacking active neurons in a receptor-mediated endocytotic pro-
cess. In nerve terminals, synaptic vesicles fuse with the presynaptic
membrane where they release the neurotransmitter into the
neuromuscular or neuroglandular junction and more active re-
ceptors are exposed [8]. Vesicle fusion is mediated by a set of SNARE
(soluble N-ethylmaleimide-sensitive fusion attachment protein
receptor) proteins. In nerve terminals affected by BoNT, light-chain
proteolytic fragments are released into the cytosol, which cleave
speciﬁc peptide bonds presenting in the synaptic fusion complex
and prevent exocytosis of the neurotransmitters containing vesicle
at the nerve terminal [1,2,9]. Each botulinum serotype cleaves a
distinct protein site. BoNT-A cleaves soluble N-ethylmaleimide-
sensitive fusion attachment protein-25 (SNAP-25), and BoNT-B
cleaves synaptobrevin [1e3]. Patients who are refractory to BoNT-
A may possibly respond to BoNT-B because of the different tar-
geting proteins.
3. Duration of BoNT effects
Each toxin inhibits exocytosis of neurotransmitters effectively
for various lengths of time, depending on differences in the SNARE-
binding proﬁles among the botulinum toxin serotypes. When used
clinically for the treatment of dystonias, BoNT-A has by far the
longest duration of activity, inducing clinical effects on neuro-
muscular activity for longer than 4 months, compared with the
durations of approximately 2 months for BoNT-B and less than 4
weeks for BoNT-E [3]. Recovery of neurotransmission is dependent
on the protease that removes BoNT as well as on the restoration of
intact SNARE proteins. In addition, structural differences in end
organs lead to effects of different durations even with the same
toxin.
4. Rationale for using BoNT for lower urinary tract
dysfunction
BoNT affects motor, sensory, and glandular functions and in-
duces anti-inﬂammation through the modulation of release of
various neurotransmitters in different kinds of tissues.
4.1. Effects on motor function
Smith et al [10] revealed signiﬁcant decreases in the release of
ACh in normal rat bladders after a BoNT-A injection, suggesting that
BoNT-A can inhibit cholinergic nerve-induced bladder activity. In
addition, contractile data suggest that onabotulinumtoxinA may
impair adenosine triphosphate (ATP) release in addition to ACh
release from isolated bladder tissue [11]. The effects of BoNT on
detrusor muscle are not permanent. Studies have shown that
onabotulinumtoxinA produces no persistent changes in the inter-
nal architecture of muscle ﬁber after recovery from paralysis.
4.2. Effects on detrusor morphology
Morphological changes after onabotulinumtoxinA injection
include subsequent compensatory nerve sprouting and creation of
extrajunctional synapses [12]. The sprouts are retracted and end-
plate functioning returns to normal when exocytosis at the parent
terminal eventually recovers [12].Multiple bladder injections may induce mechanical trauma.
Haferkamp et al [13] collected 30 bladder biopsies from 24 patients
with a diagnosis of neurogenic overactive bladder. They observed
no signiﬁcant changes in muscle cell fascicles, intercellular collagen
content, or muscle cell degeneration between biopsies taken prior
to and 3 months after BoNT-A administration. Surprisingly, in
another study, bladder specimens obtained from cystectomy in 45
patients with neurogenic overactive bladders showed that patients
who had received onabotulinumtoxinA injection had signiﬁcantly
less ﬁbrosis of the bladder wall than those who had not received
the toxin injection. In addition, a trend showed that responders to
the toxin therapy had less ﬁbrosis and edema of the bladder wall
than nonresponders [14]. Apostolidis et al [15] reported that BoNT-
A injections did not produce signiﬁcant inﬂammatory changes,
ﬁbrosis, or dysplastic changes in human bladder urothelium/sub-
urothelium after a single injection or in a limited number of repeat
treatment biopsies in patients with NDO or idiopathic detrusor
overactivity (IDO). In conclusion, BoNT bladder injection may
reverse tissue ﬁbrosis and edema in NDO.
4.3. Sensory effects
Treatment using BoNT has expanded beyond the original
concept of inhibition of muscle overactivity. Increasing evidence
exists that BoNT may also inhibit afferent neurotransmission and
have analgesic properties [16]. Changes in afferent activity may
inﬂuence pain through both direct sensory effects and indirect
central sensitization in the central nervous system. Onabotuli-
numtoxinA has been shown to inhibit the release of calcitonin
gene-related peptide, substance P, glutamate, nerve growth factor
(NGF), and ATP, which are mediators of pain sensation. In a model
of formalin-induced somatic pain and inﬂammation, rats pre-
treatedwith BoNT-A displayed signiﬁcantly reduced pain behaviors
and glutamate release from 5 hours to 12 days post injection [17].
Similar effects were observed in an acetic acid-induced bladder
pain model [18]. The concepts have been proved in the clinical use
of BoNT for interstitial cystitis, radiation cystitis, and chemical
cystitis, as well as for migraine.
Bladder urothelium not only is a barrier, but also plays an
important role in the sensory transduction mechanisms modu-
lating micturition, particularly in conditions of increased sensory
nerve transmission following chronic inﬂammation and spinal-
cord injury [19]. OnabotulinumtoxinA was shown to inhibit ATP
release from the urothelium in the bladders of rats with spinal cord
injuries [20]. The effects of BoNT are not limited solely to inhibiting
neurotransmitter release. For example, laboratory studies have
shown that transient receptor potential vanilloid 1 (i.e., capsaicin-
sensitive) receptors are released by SNARE-dependent processes
and can be inhibited by onabotulinumtoxinA treatment [21].
Giannantoni et al [22] reported that intravesical onabotuli-
numtoxinA injection reduces NGF content in the bladder tissue of
patients with NDO. The reduction of NGF leads to decreased hy-
perexcitability of C-ﬁber bladder afferents, thereby reducing NDO.
Liu et al [23] showed that NDO patients responsive to BoNT had
reduced urine NGF levels, but nonresponders had no signiﬁcant
changes. Thus, the inhibitory effects of BoNT on sensory function
may relieve somatic and visceral irritative symptoms.
4.4. Anti-inﬂammation
Chuang et al [24,25] reported that painful behavioral changes,
polymorphonuclear cell accumulation, and cyclooxygenase (COX)-2
expression in theprostateglandand intheL6ventral anddorsalhorns
inducedbycapsaicin injection into the ratprostatewere inhibited ina
dose-dependent fashionbyBoNT.OnabotulinumtoxinApretreatment
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organ to the L6 level of the spinal cord, prostatic pain, and inﬂam-
mation. This ﬁnding suggests a potential clinical beneﬁt of onabotu-
linumtoxinA for the treatment of nonbacterial prostatitis.
Furthermore, a previous study also demonstrated that intravesical
onabotulinumtoxinA administration blocked cyclophosphamide-
induced bladder inﬂammation and hyperactivity, and inhibited
COX-2 and prostaglandin E(4) expression in the bladder as well as in
the spinal cord [26]. Taken together, theseﬁndings suggest a potential
beneﬁt of BoNT treatment for prostate and bladder inﬂammatory
conditions.
5. Clinical use in the bladder
Patients with symptoms of NDO; IDO; overactive bladder, hy-
persensitive bladder, or interstitial cystitis/painful bladder syn-
drome; and noninfectious cystitis have been treated with a BoNT
injection into the bladder. An injection of 200e300 U onabotuli-
numtoxinA is most commonly used for NDO, whereas 100e200 U
onabotulinumtoxinA has been applied in treating IDO; overactive
bladder, hypersensitive bladder, or interstitial cystitis/painful
bladder syndrome; and noninfectious cystitis.
5.1. Rationale for the application of BoNT in the prostate
In a rat model, surgical denervation of the prostate by sectioning
the hypogastric nerve has been shown to induce prostatic atrophy
[27]. Previous studies using chemical denervation by injection of
BoNT into the rat prostate showed generalized atrophy and
apoptosis of glandular elements [28,29]. Cholinergic innervation of
the prostate gland has an important role in regulating the functions
of the prostate epithelium, with effects on growth and secretion,
whereas noradrenergic innervation has been implicated in the
contraction of smooth muscle and the etiology of outﬂow
obstruction accompanying BPH [29]. BoNT-induced prostatic gland
atrophy, and in some cases apoptosis, was identiﬁed in rats as well
as in dogs [28,30]. In addition, Lin et al [31] reported that an in-
jection of 200 U onabotulinumtoxinA into the canine prostate
signiﬁcantly reduced the prostate urethral pressure response to
intravenous norepinephrine and electrostimulation. They
concluded that BoNT reduces the contractile function of the pros-
tate and may attenuate the dynamic component of BPH. Intra-
prostatic BoNT injection appears to be effective in relieving the
symptoms of BPH to different degrees. However, a recent double-
blind randomized control study has not shown signiﬁcant clinical
effects in comparison with those in the placebo group [32]. The
clinical effects of BoNT on LUTS suggestive of BPH are still contro-
versial. Different doses, dilution volumes, and prostate components
may lead to different results.
5.2. Rationale for instillation of BoNT for bladder disorders
The bladder is a hollow organ that is easy to access or treat
locally through the urethra. Instillation as a mode of administering
BoNT may decrease side effects and treatment costs drastically.
Recent studies suggested the potential of liposomes as a
promising vehicle for delivery of neurotoxins into the bladder [33].
Liposomes have been proved to be biocompatible delivery agents in
the bladder. The transport of BoNT into the urothelium from lipo-
somes (Lipella Pharmaceuticals, Pittsburgh, PA, USA) was
conﬁrmed by detection of its unique effects on neurotransmitters
and proteolysis of synaptosomal-associated protein SNAP-25
through immunohistochemistry and western blotting. BoNT
entrapped inside liposomes was protected from degradation in
urine without compromising efﬁcacy, which was demonstrated byattenuation of acetic acid-induced bladder irritation in rats. These
results support the use of liposomes as an efﬁcient vehicle for
delivering botulinum toxin without injection. Clinical trials should
be conducted to assess the efﬁcacy of liposomal formulation of
BoNT and investigate whether it can reduce the risk of retention.
6. Conclusion
BoNT has been proved to provide therapeutic beneﬁts across a
wide variety of LUTS that involve muscular hypercontractility, hy-
persensitivity, and glandular hypertrophy. Advances have been
made in our understanding of how BoNT works in LUTS. However,
currently, it has been proved to be effective only for neurogenic and
idiopathic overactive bladder.
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